As of today (2024-04-19), Pfizer's share price is $25.39.
Pfizer's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.54. Hence, Pfizer's Price-to-Operating-Cash-Flow Ratio for today is 16.48.
The historical rank and industry rank for Pfizer's Price-to-Operating-Cash-Flow or its related term are showing as below:
PFE'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.31 Med: 12.55 Max: 19.12
Current: 16.46
During the past 13 years, Pfizer's highest Price-to-Operating-Cash-Flow Ratio was 19.12. The lowest was 7.31. And the median was 12.55.
Pfizer's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was $0.93.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.54.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Pfizer was -69.80% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -15.50% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 1.70% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 2.30% per year.
During the past 13 years, Pfizer's highest 3-Year average Operating Cash Flow per Share Growth Rate was 35.60% per year. The lowest was -15.50% per year. And the median was 9.85% per year.
Pfizer Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Pfizer's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Pfizer Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
|
|
|
|
|
16.74 |
14.40 |
10.35 |
10.04 |
18.67 |
|
Pfizer Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.04 |
9.76 |
14.44 |
15.74 |
18.67 |
Competitive Comparison
For the Drug Manufacturers - General subindustry, Pfizer's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pfizer Price-to-Operating-Cash-Flow Distribution
For the Drug Manufacturers industry and Healthcare sector, Pfizer's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Pfizer's Price-to-Operating-Cash-Flow falls into.
Pfizer Price-to-Operating-Cash-Flow Calculation
Pfizer's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 25.39 | / | 1.541 |
| = | 16.48 |
Pfizer's Share Price of today is $25.39.
Pfizer's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.54.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Pfizer (Pfizer) Business Description
Traded in Other Exchanges
Address
66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Executives
| Scott Gottlieb |
director |
MOLECULAR INSIGHT PHARMACEUTICALS, 160 SECOND STREET, CAMBRIDGE MA 02142 |
| Christoffel Boshoff |
officer: Executive Vice President |
66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192 |
| Jennifer B. Damico |
officer: SVP & Controller |
C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
| Payal Sahni |
officer: Executive Vice President |
ATTN: PFIZER CORP. SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017 |
| Carapezzi William R Jr |
officer: Executive Vice President |
600 MOUNTAIN AVENUE, MURRAY HILL NJ 07921 |
| Douglas M Lankler |
officer: Senior Vice President |
PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
| Mikael Dolsten |
officer: Senior Vice President |
5 GIRALDA FARMS, MADISON NJ 07940 |
| David M Denton |
officer: Chief Financial Officer & EVP |
1000 LOWE'S BOULEVARD, MOORESVILLE NC 28117 |
| William Pao |
officer: Executive Vice President |
C/O CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
| Michael Mcdermott |
officer: Executive Vice President |
C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, 235 EAST 42ND STREET NY 10017 |
| Rady A Johnson |
officer: Executive Vice President |
PFIZER INC. ATTN CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
| Alexander R Mackenzie |
officer: Executive Vice President |
C/O PFIZER CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
| Sally Susman |
officer: Senior Vice President |
767 FIFTH AVE, EOTIC LAWDER CORP, NEW YORK NY 10153 |
| Angela Hwang |
officer: Group President |
235 EAST 42ND STREET, ATTN: CORPORATE SECRETARY, NEW YORK NY 10017 |
| John D Young |
officer: Business Unit President |
C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017 |
Pfizer (Pfizer) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PFE has been successfully added to your